🚀 Apply for £10k+ grants with our Startup Launch Kit
shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

    PAR-22-216

    National Institutes of Health

    Opening date 14 Jul 2022, 12:00AM

    Closing date 1 Jul 2025, 12:00AM

    Funding Opportunity Number: PAR-22-216

    Opportunity Category: Discretionary

    CFDA Number(s): 93.393 -- Cancer Cause and Prevention Research,93.394 -- Cancer Detection and Diagnosis Research,93.395 -- Cancer Treatment Research,93.396 -- Cancer Biology Research,93.399 -- Cancer Control

    Cost Sharing or Matching Requirement: No

    Posted Date: Jul 14, 2022 12:00:00 AM EDT

    Closing Date: Jul 01, 2025 12:00:00 AM EDT

    Award Ceiling: $275000

    Award Floor: none

    Eligible Applicants: Public housing authorities/Indian housing authorities,Small businesses,Native American tribal governments (Federally recognized),City or township governments,Public and State controlled institutions of higher education,Private institutions of higher education,For profit organizations other than small businesses,County governments,Special district governments,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Native American tribal organizations (other than Federally recognized tribal governments),State governments,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Others (see text field entitled "Additional Information on Eligibility" for clarification),Independent school districts

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Agency Name: National Institutes of Health

    Description: This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

    Grantor Contact Information: NIH OER Webmaster OERWebmaster03@od.nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept